4) a “bio-prospecting agreement,” a written agreement between a bio member and a contracting party or a supplying party, which concerns (i) prior consent after information and (ii) conditions for the collection and use of regulated genetic resources, including, among other things, the distribution of benefits; I told you to do so Suppliers can request the assignment and notification of materials distributed under the OpenMTA. This article is licensed Creative Commons Attribution 4.0 International License, which allows use, release, customization, distribution and reproduction in any medium or format, provided you give the original author and source a link to the Creative Commons license and if you specify if any changes have been made. The images or other third-party material contained in this article are included in the article`s Creative Commons license, unless otherwise stated in a hardware credit. If the material is not included in the Creative Commons license of the article and your intention to use it is not authorized by law or if the authorized use exceeds, you must obtain permission directly from the copyright holder. To view a copy of this license, visit creativecommons.org/licenses/by/4.0/ valuation, option and exclusivity The purchaser may wish for exclusivity and an option for acquiring rights to the corresponding physical and intellectual property. For simple transfers without intellectual property, the NIH recommends a simple matching agreement. For materials that can be patented or for which increased protection is desired, the Uniform Biological Material Transfer Agreement (UBMTA) can be used. Many U.S. educational institutions have signed the UBMTA Masteragrement.  AUTM (formerly the Association of University Technology Managers) serves as a repository for UBMTA`s original master`s contracts and keeps the list of signatories.  UBMTA signatories must only sign a letter of execution containing the details of each transfer, since they have already agreed to all the terms of the master contract. OpenMTA certainly recovers the costs associated with the production and distribution of materials and could therefore also be used for the transfer of research reagents such as antibodies, cell lines and fluorescent proteins for which patents have expired or have never been sought. Indeed, the introduction of OpenMTA for the sharing of biological materials is particularly current, since many patented materials are now made public due to the expiry of patents.
For example, a collection of patents on green fluorescent proteins, initially aggregated and over-licensed by GEcare Lifesciences16, have all expired (Table 2).